BridgeBio
Healthcare & Life Sci
Company overview
BridgeBio develops medicines for rare genetic conditions. Attruby, also known as acoramidis, is one of its FDA-approved medicines. NULIBRY, also known as fosdenopterin, is another FDA-approved medicine from the company. In total, the company has received 3 FDA approvals for its medicines.
BridgeBio has more than 2,000 patients enrolled in its clinical trials around the world. BridgeBio is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- San Francisco, United States